Table 3.
Univariate and multivariate Cox analysis using continuous values for clinical and significant PET metrics and anthropometric parameters measured on 18FDG PET/CT
| Whole population | NSCLC | Melanoma | ||||
| Univariate Cox analysis | ||||||
| HR | P value | HR | P value | HR | P value | |
| Age | 1.00 | 0.80 | 1.00 | 0.74 | 1.00 | 0.82 |
| Sex | 1.12 | 0.22 | 0.99 | 0.95 | 1.09 | 0.55 |
| Cerebral-meningeal metastasis | 1.25 | 0.02 | 1.01 | 0.96 | 1.56 | 0.002 |
| BMI | 0.96 | 0.0003 | 0.94 | 8×10–05 | 1.00 | 0.75 |
| Weight loss | 1.07 | 9×10–05 | 1.07 | 0.002 | 1.07 | 0.049 |
| FBM | 0.95 | 8×10–05 | 0.92 | 0.0001 | 0.99 | 0.74 |
| SFM | 0.94 | 0.0002 | 0.91 | 0.0003 | 0.99 | 0.81 |
| VFM | 0.79 | 0.0006 | 0.71 | 0.0005 | 0.94 | 0.53 |
| MBM | 0.82 | 3×10–10 | 0.80 | 1×10–6 | 0.89 | 0.01 |
| LBM | 0.99 | 0.44 | 0.94 | 0.02 | 1.02 | 0.38 |
| Multivariate stepwise Cox analysis | ||||||
| Cerebral-meningeal metastasis | 1.21 | 0.053 | NA | NA | 1.50 | 0.004 |
| BMI | 1.03 | 0.10 | NA | NA | 1.03 | 0.06 |
| Weight loss | 1.07 | 0.0003 | 1.06 | 0.004 | 1.06 | 0.10 |
| FBM | NA | NA | NA | NA | NA | NA |
| SFM | 0.93 | 0.013 | 0.94 | 0.02 | NA | NA |
| VFM | NA | NA | NA | NA | NA | NA |
| MBM | 0.81 | 3×10–08 | 0.83 | 0.0002 | 0.90 | 0.02 |
BMI, body mass index; FBM, fat body mass; 18FDG, 18F-fluorodesoxyglucose; LBM, lean body mass; MBM, muscle body mass; MTV, metabolic tumor volume; NA, not available; NSCLC, non-small cell lung cancer; PET, positron emission tomography; SFM, subcutaneous fat mass; VFM, visceral fat mass.